Generate Biomedicines Inc GENB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $13.80
- Day Range
- $13.30–14.30
- 52-Week Range
- $11.00–22.67
- Bid/Ask
- $13.50 / $13.80
- Shares Outstanding
- 128.35M
- Market Cap
- $1.76B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 51.86
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
Valuation
|
Metric
|
GENB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.88 |
Price/Sales | 51.86 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GENB
|
|---|---|
Quick Ratio | 8.08 |
Current Ratio | 8.30 |
Interest Coverage | −329.66 |
Quick Ratio
GENB
Profitability
|
Metric
|
GENB
|
|---|---|
Return on Assets (Normalized) | −45.62% |
Return on Equity (Normalized) | −195.08% |
Return on Invested Capital (Normalized) | −132.55% |
Return on Assets
GENB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@<DN#J | LOCK|&?%! | $128B | |||
| Moderna Inc
MRNA
| LOCK|%$F^?m | LOCK|%! | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|P@rK?Q | LOCK|>t>lj | $76B | |||
| argenx SE ADR
ARGX
| LOCK|$R<?Dhj | LOCK|<? | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%XRrF% | LOCK|fkW | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|C?pYy#Z | LOCK|#XW^X | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|K@F^s?& | LOCK|#p%< | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|DHZW$r | LOCK|Rh | $24B | |||
| Incyte Corp
INCY
| LOCK|NqY$QsH | LOCK|#@ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|??B#Mmh | LOCK|^@D | $15B |
United States